Trial reportFrontiers in oncology2026
Dual-energy and perfusion CT for predicting response to chemo-radiotherapy in head and neck cancer: an exploratory study.
Trial report in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04019548 (Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Head and neck cancer (HNC) is a major global health issue, often linked to smoking, alcohol, and viruses (HPV, EBV). HPV-driven oropharyngeal squamous cell carcinoma (OPSCC) showed distinct biology and better response to chemoradiotherapy (CRT) than HPV-negative HNC. Despite these differences, treatment remains uniform, emphasizing the need for predictive imaging biomarkers. Dual-energy computed tomography (DECT) and perfusion computed tomography (PCT) are promising techniques for predicting treatment response, though their clinical utility remains underexplored. This exploratory study investigates whether quantitative parameters (QPs) from DECT and PCT, can predict complete response (CR) 12 months after CRT. Materials and methods: 36 HNC patients were enrolled and classified as CR or non-CR (NCR) based on RECIST 1.1 criteria at one year. Imaging was performed at baseline, 3 weeks, 3 months, and 12 months, measuring blood flow (BF), blood volume (BV), and contrast media attenuation (CMA). Statistical analyses compared CR and NCR groups, including subgroups based on HPV status. Results: Patients with CR (n=26) showed significantly higher BF and BV at 3 weeks (p<0.01), longer mean transit time (MTT) at 3 months (p<0.03), and lower CMA at 3 months (p<0.03) compared to NCR patients. In the HPV-positive subgroup, CR patients had higher BF and BV than NCR patients (p<0.02). Delta analysis revealed no significant differences except for ΔCMA (3W-0), which was lower in HPV-negative patients (p<0.04). Conclusion: In this exploratory study, DECT and PCT QPs showed potential associations with treatment response in HNC, particularly at early stages. These hypothetical findings warrant further validation in dedicated prospective studies before integration into personalized treatment strategies. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04019548, identifier NCT04019548.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.